Cargando…

The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries

PURPOSE: The aim of this study is to investigate the role of health-related quality-of-life (QoL) data in relative effectiveness assessments (REAs) of new anti-cancer drugs across European jurisdictions, during health technology assessment procedures. METHODS: Comparative analysis of guidelines and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kleijnen, Sarah, Leonardo Alves, Teresa, Meijboom, Kim, Lipska, Iga, De Boer, Anthonius, Leufkens, Hubertus G., Goettsch, Wim G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548837/ https://www.ncbi.nlm.nih.gov/pubmed/28401419 http://dx.doi.org/10.1007/s11136-017-1574-9

Ejemplares similares

Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study
por: Makady, Amr, et al.
Publicado: (2018)

Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

Statins and Risk of Lower Limb Revision Surgery: The Influence of Differences in Study Design Using Electronic Health Records From the United Kingdom and Denmark
por: Lalmohamed, Arief, et al.
Publicado: (2016)

Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
por: Hogervorst, Milou A, et al.
Publicado: (2023)

Demographics in the 2020s—Longevity as a challenge for pharmaceutical drug development, prescribing, dispensing, patient care and quality of life
por: Stegemann, Sven, et al.
Publicado: (2020)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Use of Social Media in the Assessment of Relative Effectiveness: Explorative Review With Examples From Oncology
por: Kalf, Rachel RJ, et al.
Publicado: (2018)

Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders
por: Mulder, Jorn, et al.
Publicado: (2021)

Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study
por: Wang, Ting, et al.
Publicado: (2020)

Psychometric evaluation of the Mental Health Quality of Life (MHQoL) instrument in seven European countries
por: Enzing, Joost J., et al.
Publicado: (2022)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
por: A Vreman, Rick, et al.
Publicado: (2020)

Essential Medicines Are More Available than Other Medicines around the Globe
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
por: Vreman, Rick A., et al.
Publicado: (2019)

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
por: Vreman, Rick A., et al.
Publicado: (2020)

Information Patients With Melanoma Spontaneously Report About Health-Related Quality of Life on Web-Based Forums: Case Study
por: Kalf, Rachel R J, et al.
Publicado: (2021)

Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe
por: Vreman, Rick A., et al.
Publicado: (2020)

Diabetes-related quality of life in six European countries measured with the DOQ-30
por: Pilv, Liina, et al.
Publicado: (2021)

The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children
por: Kreeftmeijer-Vegter, Annemarie Rosan, et al.
Publicado: (2014)

Quality of reporting of drug exposure in pharmacoepidemiological studies
por: Hempenius, Mirjam, et al.
Publicado: (2020)

Predictors of orphan drug approval in the European Union
por: Heemstra, Harald E., et al.
Publicado: (2008)

Piloting a generic cancer consumer quality index in six European countries
por: Wind, Anke, et al.
Publicado: (2016)

Essential medicines for breast cancer in low and middle income countries
por: Bazargani, Y. T., et al.
Publicado: (2015)

Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries
por: Bazargani, Y. T., et al.
Publicado: (2018)

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2020)

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars
por: Alsamil, Ali M., et al.
Publicado: (2021)

Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries
por: Leopold, Christine, et al.
Publicado: (2014)

Health-related quality of life of multiple sclerosis patients: a European multi-country study
por: Visser, Laurenske A., et al.
Publicado: (2021)

Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries
por: Leopold, Christine, et al.
Publicado: (2012)

Recommendations for patient involvement in health technology assessment in Central and Eastern European countries
por: Jakab, Ivett, et al.
Publicado: (2023)

Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries
por: Bosch, Annet M, et al.
Publicado: (2015)

Influence of Active and Healthy Ageing on Quality of Life Changes: Insights from the Comparison of Three European Countries
por: Ayala, Alba, et al.
Publicado: (2021)

Risk of myocardial infarction associated with non‐steroidal anti‐inflammatory drugs: Impact of additional confounding control for variables collected from self‐reported data
por: Bakhriansyah, Mohammad, et al.
Publicado: (2019)

Health-related quality of life in seven European countries throughout the course of the COVID-19 pandemic: evidence from the European COvid Survey (ECOS)
por: König, Hans-Helmut, et al.
Publicado: (2023)

Environmental Impact of Diets in 10 European countries
por: Alves, R, et al.
Publicado: (2023)

Efficacy gap between phase II and subsequent phase III studies in oncology
por: Vreman, Rick A., et al.
Publicado: (2020)

The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries
por: Lukas, Kati, et al.
Publicado: (2011)

Health-Related Quality of Life and Perceived Burden of Informal Caregivers of Patients with Rare Diseases in Selected European Countries
por: Valcárcel-Nazco, Cristina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t7e62m6md8n4gevjj8t7vl3fmb